“…Given the potential for live attenuated influenza virus vaccines to confer a great breadth of heterologous cross-protection (1,2,6,35), we recently conducted a study evaluating cold-adapted A/Ann Arbor/6/1960 (AA CA), an H2 influenza virus used as the backbone of the seasonal live attenuated influenza A virus vaccine currently licensed in the United States (3). However, as H2 influenza virus continues to circulate widely and appear in migratory birds (10,24,26), in poultry markets (20), and in swine (21), with evidence of interregional gene transmission (19,22), a more extensive evaluation of recent isolates may be warranted in the selection of a potential H2 pandemic vaccine candidate.…”